FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007479818> ?p ?o ?g. }

• W2007479818 endingPage "555" @default.
• W2007479818 startingPage "550" @default.
• W2007479818 abstract "Purpose: To report the short-term efficacy and safety of intravitreal bevacizumab (Avastin) injection with panretinal laser photocoagulation (PRP) in patients with high-risk proliferative diabetic retinopathy (PDR) according to the Early Treatment Diabetic Retinopathy Study criteria. Methods: A prospective, interventional case series study was conducted in 17 patients (20 eyes) with high-risk PDR, who were treated with intravitreal bevacizumab (2.5 mg) followed by PRP when the peripheral vitreous became clear or 2 weeks after injection. Patients underwent complete ophthalmic evaluation, including Snellen visual acuity and fluorescein angiography at baseline, 1, 3, and 6 months after bevacizumab injection. Main outcome measures included the serial changes in visual acuity, vitreous clear-up time, and neovascularization on the disc (NVD) regression time. Results: All patients had obvious reduction in angiographic leakage and involution of retinal neovascularization (NV) at the 1- and 3-month follow-up. The mean follow-up time was 7.5 months. The vitreous hemorrhage (VH) showed a partial resolution as early as 1 week, and complete regression at 3 months. The mean vitreous clear-up time after intravitreal Avastin was 8.5±2.2 weeks. The mean time interval from intravitreal Avastin to NVD regression was 10.8±3.4 weeks. Mean logarithm of the minimum angle resolution visual acuity improved from 1.03 at baseline to 0.36 at 1-month, 0.38 at 3-month, and 0.48 at the 6-month follow-up (P<0.01). Three eyes (18%) required vitrectomy surgery during follow-up. The indication for vitrectomy was dense, persistent VH in 2 eyes, and focal tractional retinal detachment (TRD) in 1 eye. Recurrent retinal NV with minor preretinal hemorrhage was observed in 6 eyes (30%) 3 months after the first injection, and resolved after repeated bevacizumab injections. Patients received an average of 1.4 injections (range: 1–2). Seven eyes (35%) underwent 2 injections. One eye (5%) had ocular complication of PDR progression to TRD. No systemic adverse events were observed following injections. Conclusions: Short-term results suggest combined intravitreal bevacizumab and PRP achieved rapid clearance of VH, regression of retinal NV, and visual improvement in the treatment of high-risk PDR. Long-term study is warranted to assess the long-term efficacy and safety." @default.
• W2007479818 created "2016-06-24" @default.
• W2007479818 creator A5002279928 @default.
• W2007479818 creator A5021342511 @default.
• W2007479818 creator A5088498135 @default.
• W2007479818 creator A5090110109 @default.
• W2007479818 date "2013-07-01" @default.
• W2007479818 modified "2023-10-16" @default.
• W2007479818 title "Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy" @default.
• W2007479818 cites W1969169427 @default.
• W2007479818 cites W1987590493 @default.
• W2007479818 cites W1989729487 @default.
• W2007479818 cites W1993760044 @default.
• W2007479818 cites W2007910630 @default.
• W2007479818 cites W2015843817 @default.
• W2007479818 cites W2019113826 @default.
• W2007479818 cites W2029126623 @default.
• W2007479818 cites W2045390750 @default.
• W2007479818 cites W2047279031 @default.
• W2007479818 cites W2054438872 @default.
• W2007479818 cites W2072419304 @default.
• W2007479818 cites W2105913241 @default.
• W2007479818 cites W2122595579 @default.
• W2007479818 cites W2128535483 @default.
• W2007479818 cites W2137893922 @default.
• W2007479818 cites W2324588265 @default.
• W2007479818 cites W2406931263 @default.
• W2007479818 cites W4244248663 @default.
• W2007479818 cites W4255957248 @default.
• W2007479818 doi "https://doi.org/10.1089/jop.2012.0202" @default.
• W2007479818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3708621" @default.
• W2007479818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23495932" @default.
• W2007479818 hasPublicationYear "2013" @default.
• W2007479818 type Work @default.
• W2007479818 sameAs 2007479818 @default.
• W2007479818 citedByCount "46" @default.
• W2007479818 countsByYear W20074798182013 @default.
• W2007479818 countsByYear W20074798182014 @default.
• W2007479818 countsByYear W20074798182015 @default.
• W2007479818 countsByYear W20074798182016 @default.
• W2007479818 countsByYear W20074798182017 @default.
• W2007479818 countsByYear W20074798182018 @default.
• W2007479818 countsByYear W20074798182019 @default.
• W2007479818 countsByYear W20074798182020 @default.
• W2007479818 countsByYear W20074798182021 @default.
• W2007479818 countsByYear W20074798182022 @default.
• W2007479818 countsByYear W20074798182023 @default.
• W2007479818 crossrefType "journal-article" @default.
• W2007479818 hasAuthorship W2007479818A5002279928 @default.
• W2007479818 hasAuthorship W2007479818A5021342511 @default.
• W2007479818 hasAuthorship W2007479818A5088498135 @default.
• W2007479818 hasAuthorship W2007479818A5090110109 @default.
• W2007479818 hasBestOaLocation W20074798182 @default.
• W2007479818 hasConcept C118487528 @default.
• W2007479818 hasConcept C126322002 @default.
• W2007479818 hasConcept C134018914 @default.
• W2007479818 hasConcept C141071460 @default.
• W2007479818 hasConcept C2776694085 @default.
• W2007479818 hasConcept C2777104736 @default.
• W2007479818 hasConcept C2777802072 @default.
• W2007479818 hasConcept C2778257484 @default.
• W2007479818 hasConcept C2778271429 @default.
• W2007479818 hasConcept C2779829184 @default.
• W2007479818 hasConcept C2780248432 @default.
• W2007479818 hasConcept C2780394083 @default.
• W2007479818 hasConcept C2781242345 @default.
• W2007479818 hasConcept C555293320 @default.
• W2007479818 hasConcept C71924100 @default.
• W2007479818 hasConceptScore W2007479818C118487528 @default.
• W2007479818 hasConceptScore W2007479818C126322002 @default.
• W2007479818 hasConceptScore W2007479818C134018914 @default.
• W2007479818 hasConceptScore W2007479818C141071460 @default.
• W2007479818 hasConceptScore W2007479818C2776694085 @default.
• W2007479818 hasConceptScore W2007479818C2777104736 @default.
• W2007479818 hasConceptScore W2007479818C2777802072 @default.
• W2007479818 hasConceptScore W2007479818C2778257484 @default.
• W2007479818 hasConceptScore W2007479818C2778271429 @default.
• W2007479818 hasConceptScore W2007479818C2779829184 @default.
• W2007479818 hasConceptScore W2007479818C2780248432 @default.
• W2007479818 hasConceptScore W2007479818C2780394083 @default.
• W2007479818 hasConceptScore W2007479818C2781242345 @default.
• W2007479818 hasConceptScore W2007479818C555293320 @default.
• W2007479818 hasConceptScore W2007479818C71924100 @default.
• W2007479818 hasIssue "6" @default.
• W2007479818 hasLocation W20074798181 @default.
• W2007479818 hasLocation W20074798182 @default.
• W2007479818 hasLocation W20074798183 @default.
• W2007479818 hasOpenAccess W2007479818 @default.
• W2007479818 hasPrimaryLocation W20074798181 @default.
• W2007479818 hasRelatedWork W1969169427 @default.
• W2007479818 hasRelatedWork W2061367013 @default.
• W2007479818 hasRelatedWork W2080574659 @default.
• W2007479818 hasRelatedWork W2111143628 @default.
• W2007479818 hasRelatedWork W2347383686 @default.
• W2007479818 hasRelatedWork W2369313613 @default.
• W2007479818 hasRelatedWork W2375157345 @default.
• W2007479818 hasRelatedWork W2383458307 @default.
• W2007479818 hasRelatedWork W3031867745 @default.

• next